Does UnitedHealthcare Cover Wegovy? The 2026 Coverage Reality

Trust signals

> Reviewed by FormBlends Medical Team · Last updated May 2026 · 13 sources cited

As of May 2026. Confirm directly with your plan. Coverage varies by employer plan, region, and time. Always confirm with your specific plan administrator.

Key Takeaways

• Many UHC commercial plans cover Wegovy for obesity with PA via OptumRx, but employer plan design controls whether weight-loss drug coverage exists at all
• The PA criteria track FDA labeling: BMI 30+, or BMI 27+ with a weight-related comorbidity. Some plans add stricter thresholds
• UHC Medicare Advantage covers Wegovy only for the cardiovascular indication under the November 2024 CMS rule. Weight loss alone is excluded under Part D statute
• The largest single barrier to UHC Wegovy coverage is employer plan exclusion of weight-loss drugs, not OptumRx PA strictness
• The Novo Nordisk Wegovy Savings Card and the patient assistance program are common bridges when coverage falls short

Direct answer

UnitedHealthcare commercial plans often cover Wegovy for chronic weight management when the OptumRx prior authorization is approved. The PA requires BMI 30 or higher, or BMI 27 or higher with at least one weight-related comorbidity, plus documented engagement in lifestyle intervention. The biggest single coverage variable is whether the employer plan includes weight-loss drug benefits at all. Many do not. UHC Medicare Advantage covers Wegovy only for the cardiovascular indication, not for weight loss alone.

Table of contents

1. UHC's Wegovy coverage posture in 2026
2. The OptumRx PA criteria for Wegovy
3. The BMI threshold rules in detail
4. Comorbidity documentation: what counts and what doesn't
5. Step therapy and lifestyle intervention requirements
6. Employer plan layering: the single biggest variable
7. The November 2024 CMS rule and UHC Medicare Advantage
8. Cost-sharing math: with the manufacturer card and without
9. Reading the OptumRx denial letter for Wegovy
10. Building the Wegovy appeal: what works
11. External review when the internal appeal fails
12. If UHC won't cover: alternatives including the FormBlends 503A path
13. Contrary view: the actuarial case for tight Wegovy PA
14. Decision framework
15. FAQ
16. Sources

UHC's Wegovy coverage posture in 2026

UHC's coverage of Wegovy has expanded since the drug's FDA approval in June 2021 for chronic weight management. The expansion has been uneven across plan types. Commercial plans with weight-loss drug coverage benefit designs cover Wegovy with PA. Commercial plans without weight-loss drug coverage do not cover Wegovy regardless of clinical criteria. Medicare Advantage plans cover Wegovy only for the cardiovascular indication after the November 2024 CMS rule.

The 2024 FDA approval of Wegovy for cardiovascular risk reduction in adults with overweight or obesity and established cardiovascular disease changed the regulatory landscape. UHC Medicare Advantage plans added Wegovy to their Part D formularies for that specific indication. The change does not affect coverage for weight loss alone in Medicare Advantage.

The OptumRx PA criteria for Wegovy

OptumRx PA for Wegovy on most UHC commercial plans asks for:

• BMI documented (measurement date, height, weight)
• BMI 30 or higher, or BMI 27 or higher with documented weight-related comorbidity
• Age 18 or older for the adult indication; documentation for pediatric (12 and older) follows the pediatric BMI percentile criterion
• Documentation of prior or concurrent lifestyle intervention (often 3 to 6 months of structured diet and exercise attempts)
• For cardiovascular indication: established ASCVD documented

Approvals are typically issued for 12 months. Renewal requires the prescriber to attest continued benefit, usually defined as 5% weight loss from baseline within 6 months.

The BMI threshold rules in detail

The FDA labeling for Wegovy splits eligibility by BMI:

BMI category	Wegovy eligibility under FDA labeling	Common UHC plan requirements
Below 27	Not eligible	Not covered
27 to 29.9	Eligible with comorbidity	Requires documented comorbidity
30 or higher	Eligible for obesity indication	Standard PA path
Pediatric (12+) with BMI at 95th percentile or higher for age and sex	Eligible	Pediatric-specific PA

BMI is calculated as weight in kilograms divided by height in meters squared, or weight in pounds divided by height in inches squared, multiplied by 703. The PA documentation should include the measurement date because BMI changes over time and stale measurements raise reviewer concerns.

Comorbidity documentation: what counts and what doesn't

For BMI 27 to 29.9 patients, comorbidity documentation is the gatekeeper. Conditions that typically support Wegovy coverage:

• Type 2 diabetes (E11.x)
• Hypertension (I10)
• Dyslipidemia (E78.x)
• Obstructive sleep apnea (G47.33)
• Cardiovascular disease, including atherosclerotic coronary disease, stroke, peripheral artery disease
• Non-alcoholic fatty liver disease in some plans

The documentation should show the diagnosis is current, not just a historical mention. Lab values, imaging findings, or specialist notes strengthen the PA.

Step therapy and lifestyle intervention requirements

UHC and OptumRx commonly require documentation of lifestyle intervention before or alongside Wegovy. The documentation can include:

• Records of a structured diet program (commercial program enrollment, dietitian visits)
• Exercise plan and adherence documentation
• Chart notes from the primary care visits where weight management was discussed
• Weight history showing the trajectory and prior attempts

Some plans accept concurrent intervention (engagement while on Wegovy). Others require a documented prior attempt before approval. The PA criteria specify the requirement.

Step therapy with other GLP-1 drugs is less common for Wegovy than for diabetes drugs, but some UHC plans require a trial of Saxenda or another weight-loss medication before Wegovy.

Employer plan layering: the single biggest variable

The most important variable in UHC Wegovy coverage is the employer plan design. UHC services many self-funded employer plans. Under ERISA, the employer sets the benefit design. The same UHC card from two different employers can produce two different coverage outcomes.

Common employer plan variations:

• Plans that exclude weight-loss drugs entirely (the most common form of exclusion)
• Plans that cover Wegovy with tighter criteria than UHC standard
• Plans that cover Wegovy with broader criteria than UHC standard
• Plans that require enrollment in an employer-sponsored weight-management program
• Plans that limit Wegovy to a specific number of months of coverage

The Summary of Benefits and Coverage and the Evidence of Coverage are the authoritative documents. Read them before assuming UHC will or will not cover Wegovy for your situation.

The November 2024 CMS rule and UHC Medicare Advantage

CMS finalized a rule in November 2024 allowing Part D plans to cover GLP-1 medications when prescribed for a cardiovascular indication, even when the medication is also approved for weight loss. UHC Medicare Advantage plans added Wegovy to their Part D formularies for the cardiovascular indication following the rule.

The clinical basis is the SELECT trial (Lincoff et al., NEJM 2023), which showed Wegovy reduced major adverse cardiovascular events in adults with overweight or obesity and established cardiovascular disease. The FDA approved the cardiovascular indication for Wegovy in March 2024.

For UHC Medicare Advantage members, Wegovy coverage under the CMS rule requires:

• Documented established cardiovascular disease (prior MI, prior stroke, prior peripheral artery disease, prior coronary revascularization)
• BMI 27 or higher
• Prescription written for the cardiovascular indication, not for weight loss alone
• Standard Part D PA criteria met

The Part D $2,000 annual out-of-pocket cap applies. Manufacturer savings card is not available to Medicare beneficiaries.

Cost-sharing math: with the manufacturer card and without

Wegovy commercial cost-sharing varies widely. List price for Wegovy as of May 2026 is approximately $1,350 per 28-day supply at retail. Plan negotiated rates and tier copays reduce member cost substantially when coverage is in place.

Scenario	Approximate monthly cost
UHC commercial, Wegovy covered, with manufacturer card	$0 for eligible patients up to a savings cap (terms vary)
UHC commercial, Wegovy covered, no card	$25 to $200 copay depending on plan tier
UHC commercial, Wegovy not covered, no card	$1,300 to $1,450 cash price
UHC commercial, Wegovy not covered, with savings card	$650 for eligible cash-pay patients (terms vary)
UHC Medicare Advantage, CV indication covered	$50 to $150 in initial coverage, up to $2,000 OOP cap
UHC Medicare Advantage, weight-loss only	Not covered

The Novo Nordisk Wegovy Savings Card has been the most-used cost-reduction tool for commercial patients. Terms and eligibility shift; the Novo Nordisk site is authoritative.

Reading the OptumRx denial letter for Wegovy

OptumRx Wegovy denial letters specify the reason. Common categories:

• BMI does not meet criteria. Documentation showed BMI below threshold, or BMI 27 to 29.9 without documented comorbidity. Fix: confirm BMI is correctly documented and check for comorbidity coding.
• Lifestyle intervention not documented. The PA did not include the diet, exercise, or weight-management program documentation. Fix: resubmit with the documentation in the chart notes.
• Plan does not cover weight-loss drugs. Employer exclusion. No appeal will overturn the exclusion.
• PA required but not submitted. Procedural fix.
• Step therapy required. Trial of a preferred weight-loss drug not documented. Fix: trial the preferred drug or file an exception.
• Quantity limit exceeded. Standard quantity is one dose level per 28 days during titration; once at maintenance, one 2.4 mg pen per 28 days.

Building the Wegovy appeal: what works

A strong Wegovy appeal letter from the prescriber covers:

1. The BMI with measurement date and the method of measurement
2. The comorbidity diagnoses with ICD-10 codes and supporting evidence (lab values, imaging, specialist notes)
3. The lifestyle intervention history with specific dates, programs, and outcomes
4. The clinical rationale for Wegovy specifically
5. The plan's PA criteria addressed line by line
6. A clear ask: overturn the denial and approve for the requested duration

Generic appeal letters that do not address the specific denial reason rarely succeed. The letter should look like it was written for this case, not a template.

External review when the internal appeal fails

If OptumRx and UHC uphold the denial on internal appeal, external review under ACA Section 2719 applies for most commercial plans. The reviewer is an independent physician with relevant specialty experience. The decision is binding on UHC.

The deadline is typically 4 months from the final internal denial. The form arrives with the final denial letter. Decisions arrive within 45 days standard, 72 hours expedited.

For an employer plan that excludes weight-loss drugs, external review will not overturn the exclusion. The reviewer reviews medical necessity, not benefit design.

If UHC won't cover: alternatives including the FormBlends 503A path

When UHC will not cover Wegovy, the realistic alternatives are:

• The Novo Nordisk Wegovy Savings Card for commercial enrollees, which can reduce cost to roughly $650 per month for cash-pay patients (eligibility-dependent, terms shift)
• The Novo Nordisk patient assistance program for income-qualified patients
• 503A compounded semaglutide via telehealth, which is a different product

503A compounded semaglutide is the same active molecule as Wegovy but at different dose preparations and is not FDA-approved. The product is prepared individually for each patient by a state-licensed 503A pharmacy. FormBlends works with state-licensed 503A pharmacies and licensed clinicians for clinically eligible patients. The decision belongs with the patient and a prescriber.

The 503A path is cash-pay. It is not billable to UHC or any commercial insurer. For patients who cannot use the Wegovy Savings Card or patient assistance, it is one path to GLP-1 therapy when brand-name access is blocked.

Contrary view: the actuarial case for tight Wegovy PA

UHC's Wegovy PA criteria can feel onerous, especially for patients meeting BMI 27 to 29.9 who must document comorbidity. The actuarial defense has substance.

Wegovy at $1,350 per month is one of the most expensive chronic drugs in the formulary. The STEP 1 trial (Wilding et al., NEJM 2021) showed mean weight loss of about 14.9% over 68 weeks. Real-world adherence and discontinuation are lower than trial data. Patients who stop Wegovy regain substantial weight (STEP 4 extension data, Rubino et al., JAMA 2021). Lifetime cost projections for chronic GLP-1 therapy strain plan budgets, which translate to higher member premiums.

The PA criteria ensure that members starting Wegovy have a clinical situation that matches the trial population. The argument against the criteria is that they delay care and add friction. Both views have weight. The practical takeaway: build the file correctly the first time and the friction is small.

Decision framework

If your UHC plan covers weight-loss drugs and you meet BMI criteria: file the PA. Build the file with BMI documentation, comorbidity diagnoses (if BMI 27 to 29.9), and lifestyle intervention history.

If your UHC employer plan excludes weight-loss drugs: the PA appeal will not overturn the exclusion. Pursue the Wegovy Savings Card, patient assistance, or 503A compounded.

If you are on UHC Medicare Advantage with established cardiovascular disease: Wegovy may be coverable under the November 2024 CMS rule for the CV indication. Discuss with your prescriber.

If you are on UHC Medicare Advantage without cardiovascular disease and want Wegovy for weight loss: the Part D weight-loss exclusion applies. Coverage is not available. Cash, assistance, or 503A.

FAQ

Does UHC cover Wegovy? For obesity, often yes with PA on plans that include weight-loss drug coverage. For Medicare Advantage, only for the cardiovascular indication.

What's the BMI threshold? 30 or higher, or 27 or higher with a weight-related comorbidity.

Why was I denied? BMI not met, no comorbidity documented, no lifestyle intervention, employer exclusion, step therapy, or quantity limit.

How do I appeal? File with OptumRx within the deadline. Address the specific denial reason with specific evidence.

What if my employer excluded weight-loss drugs? Internal appeal will not overturn the exclusion. Manufacturer card, assistance, or 503A.

Does Medicare Advantage cover Wegovy? Only for the cardiovascular indication under the November 2024 CMS rule.

What's the cost on UHC? Manufacturer card can reduce to $0 with coverage; $25 to $200 copay without card; $1,300+ uncovered cash.

Sources

1. UnitedHealthcare commercial formulary documents. 2026.
2. OptumRx clinical policy: Wegovy and GLP-1 receptor agonists for weight management. 2026.
3. U.S. Food and Drug Administration. Wegovy prescribing information including the SELECT cardiovascular indication.
4. Lincoff AM, et al. Semaglutide and cardiovascular outcomes in obesity (SELECT). NEJM. 2023;389:2221-2232.
5. Wilding JPH, et al. Once-weekly semaglutide in adults with overweight or obesity (STEP 1). NEJM. 2021;384:989-1002.
6. Rubino D, et al. Effect of continued vs withdrawn semaglutide (STEP 4). JAMA. 2021;325:1414-1425.
7. Centers for Medicare and Medicaid Services. Final rule on Part D coverage of GLP-1 for cardiovascular indications. November 2024.
8. Social Security Act, Section 1860D-2(e)(2). Excluded drugs under Part D.
9. Affordable Care Act, Section 2719 external review.
10. Novo Nordisk. Wegovy Savings Card program terms. 2026.
11. American Heart Association and American College of Cardiology. Obesity and cardiovascular disease guidance.
12. Endocrine Society. Obesity pharmacotherapy clinical practice guideline.
13. U.S. Food and Drug Administration. 503A compounding regulations.

Footer disclaimers

Platform Disclaimer. FormBlends operates a telehealth platform that connects patients with licensed clinicians. We do not adjudicate UHC claims or determine benefits. Descriptions of UHC and OptumRx policies reflect publicly available materials as of May 2026 and may change.

Compounded Medication Notice. Compounded semaglutide is prepared by a state-licensed 503A pharmacy on individual prescriptions. It is not FDA-approved, not therapeutically equivalent to brand-name Wegovy, and clinical equivalence should not be assumed. A prescribing clinician should be involved in the decision.

Results Disclaimer. Coverage outcomes and weight-loss results vary. The criteria, costs, and trial data described here are general and do not predict outcomes for any individual.

Trademark Notice. Wegovy, Ozempic, Saxenda, and Rybelsus are registered trademarks of Novo Nordisk A/S. Mounjaro and Zepbound are registered trademarks of Eli Lilly and Company. UnitedHealthcare and OptumRx are registered trademarks of UnitedHealth Group Inc. FormBlends is independent and not affiliated with these companies.